波普瑞韦合成路线图解
Graphical Synthetic Routes of Boceprevir
摘要
波普瑞韦（boceprevir，1），化学名为（1R，2S,5S）-N-（4-氨基-1-环丁基-3，4-二氧代丁烷-2-基）-3-[（2S）-2-（叔丁胺基甲酰胺基）-3，
出处
《中国医药工业杂志》
CAS
CSCD
北大核心
2014年第5期491-494,共4页
Chinese Journal of Pharmaceuticals
参考文献17
-
1徐芹,董金华.Boceprevir[J].中国药物化学杂志,2011,21(5):409-410. 被引量：3
-
2陈本川,陈历胜.抗丙型肝炎病毒药——Boceprevir[J].医药导报,2012,31(1):127-131. 被引量：2
-
3Saksena AK,Girijavallabhan VM,Lovey RG,et al.Peptides as NS3-serine protease inhibitors of hepatitis C virus:US,7012066[P].2006-03-14.(CA 2007,146:229614).
-
4Venkatraman S,Bogen SL,Arasappan A,et al.Discovery of(1R,SS)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl) amino]-carbonyl]amino]-3,3-dimethyl-1-oxobuty 1]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide(SCH 503034),a selective,potent,orally bioavailable hepatitis C virus NS3 protease inhibitor:a potential therapeutic agent for the treatment of hepatitis C infection[J].J Med Chem,2006,49(20):6074-6086.
-
5Chen MZ,Green MD,Zhang FC.Process and intermediates for the preparation of 3-(amino)-3-cyclobutylmethyl-2-hydroxypropionamide or salts thereof:WO,2004113272[P].2004-12-29.(CA2004,142:93423).
-
6Morgan A J,Nguyen S,Uttamsingh V,et al.Design and synthesis of deuterated boceprevir analogs with enhanced pharmacokinetic properties[J].J Labelled Compd Radiopharm,2011,54(9):613-624.
-
7Dong S,Park JH,Vater EJ.Process for the synthesis of 3-amino-3-cyclobutylmethyl-2-hydroxypropionamide or salts thereof:WO,2009085858[P].2009-07-09.(CA 2009,151:123566).
-
8Park JH,Vater EJ,Dong S,et al.Preparation of 3-amino3-(cyclobutylmethyl)-2-(hydroxy)-propionamide hydrochloride:WO,2008082486[P].2008-07-10.(CA2008,149:129089).
-
9Park JH,Sudhakar A,Wong GS,et al.Process and intermediates for the preparation of(1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylates or salts thereof:WO,2004113295[P].2004-12-29.(CA 2004,142:93671).
-
10Wu G,Chen FX,Rashatasakhon P,et al.Process for the preparation of 6,6-dimethyl 3-azabicyclo-[3.1.0]-hexane compounds and enantiomeric salts thereof:WO,2007075790[P].2007-07-05.(CA 2007,147:143273).
二级参考文献4
-
1屈莉红,陈良,王介非.HCV NS3蛋白酶及抑制剂的研究进展[J].肝脏,2007,12(3):203-205. 被引量：6
-
2VENKATRAMAN S, BOGEN S L, ARASAPPAN A, et al. Discovery of ( 1R,5 S ) -N- [ 3 -amino-I - (cyclobutylmethyl) -2, 3-dioxopropyl ] -3- [ 2 ( S ) - [ [ [ ( 1,1 -dimethylethyl ) amino ] carbonyl ] amino ] -3,3-dimethyl-1 -oxobutyl ] -6,6-dimethyl-3- azabicyclo [ 3.1.0 ] hexan-2 ( S ) -carboxamide ( SCH503034 ), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection [ J ]. J Med Chem, 2006,49 ( 20 ) : 6074 - 6086.
-
3CAMPAS C, RANDIAN R, BOLOS J, et al. Boceprevir [ J ]. Drugs Future,2009,34 (9) :697 - 707.
-
4WU G,XIE J, RASHATASAKHON P, et al. Oxidation process for the preparation of N- [ 3-amino-1 - ( cyclobutylmeth- yl ) -2,3-dioxopropyl ] -3 - { N- [ ( tert-butylamino ) carbonyl ] -3 - methyl- L-valyl [ -6,6-dimethyl-3-azabicyclo [ 3.1.0 ] hexane- 2-carboxamide and related compounds: US, 20070149459 A1 [ P]. 2007 -06 -28.
共引文献3
-
1梁鑫,展鹏,刘新泳.波西普韦合成路线图解[J].中国医药工业杂志,2013,44(12):1311-1313.
-
2杨晓宇,王菊仙.抗丙型肝炎病毒新药及治疗方案研究进展[J].中国新药杂志,2014,23(22):2624-2630. 被引量：10
-
3齐燕,张冉,严舒.专利视角下丙肝相关研究发展态势剖析[J].世界科技研究与发展,2020,42(5):493-509. 被引量：1
-
1徐晨,张根元,王德才,戈文兰.HPLC测定片剂中的盐酸普拉克索[J].华西药学杂志,2014,29(4):428-430. 被引量：4
-
2周璞,黄玉仙.抗丙型肝炎药物波普瑞韦临床研究新进展[J].中国感染与化疗杂志,2013,13(6):499-503.
-
3张翼（编译）.美国FDA批准丙肝治疗新药波普瑞韦[J].药品评价,2011,8(14):33-33.
-
4张小林,胡延雷,高艳.1-氯-4-甲磺酰基丁烷的合成[J].中国新药杂志,2008,17(4):308-309.
-
5许寅,姚晓英,董平.抗丙型肝炎病毒新药波普瑞韦和替拉瑞韦[J].药学服务与研究,2014,14(4):308-311. 被引量：1
-
6王俊杰.波普瑞韦联合聚乙二醇干扰素／利巴韦林治疗HCV患者合并HIV感染的效果研究：二阶段随机双盲对照试验[J].中华预防医学杂志,2013,47(11):1035-1035.
-
7FDA连线[J].世界临床药物,2011,32(6):380-380.
-
8左志辉,王卫.顶空毛细管气相色谱法测定培哚普利叔丁胺盐中的有机溶剂残留[J].药物评价研究,2014,37(4):352-354. 被引量：1
-
9邵江勇,吴范宏.阿立哌唑的合成[J].中国新药杂志,2006,15(15):1274-1275. 被引量：3
-
10梁鑫,展鹏,刘新泳.波西普韦合成路线图解[J].中国医药工业杂志,2013,44(12):1311-1313.
